In an important scientific achievement for women’s health, two large Phase III clinical trials — The Ring Study and ASPIRE — have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women. Developed by the nonprofit International Partnership for Microbicides (IPM), the monthly ring is the first long-acting HIV prevention method designed for women, who bear the greatest burden of the global HIV/AIDS epidemic. IPM plans to apply for regulatory approval to license the product.
To read more on these studies, please click on the pdf here.
Our Bixby Director, Dr. Ndola Prata is on the Board of Directors for the International Partnership for Microbicides (IPM).